Drug intelligence / Profile preview

NPJ5008

Development stage: Phase 1
Lead developer: Norgine
Modality: Small Molecules
Administration: Intravenous

Overview

NPJ5008 is a novel formulation of dantrolene sodium, developed to shorten preparation and administration times compared to the standard dantrolene formulation, Dantrium. It is used for treating malignant hyperthermia, a rare life-threatening pharmacogenetic disorder that occurs in response to volatile anaesthetic agents. NPJ5008 acts as a postsynaptic skeletal muscle relaxant by stabilizing defective ryanodine receptors in the sarcoplasmic reticulum, thus preventing the release of calcium ions necessary for muscle contraction.

Targets

RYR1 (Ryanodine receptor 1)

Beyond the preview

Go deeper on NPJ5008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPJ5008.